Home Cart Sign in  
Chemical Structure| 398493-79-3 Chemical Structure| 398493-79-3

Structure of PHA-680632
CAS No.: 398493-79-3

Chemical Structure| 398493-79-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PHA-680632 is potent inhibitor of Aurora A, B and C with IC50 of 27 nM, 135 nM and 120 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PHA-680632

CAS No. :398493-79-3
Formula : C28H35N7O2
M.W : 501.62
SMILES Code : O=C(N(C1)CC2=C1C(NC(C3=CC=C(N4CCN(C)CC4)C=C3)=O)=NN2)NC5=C(CC)C=CC=C5CC
MDL No. :MFCD16038900
InChI Key :OBWNXGOQPLDDPS-UHFFFAOYSA-N
Pubchem ID :11249084

Safety of PHA-680632

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of PHA-680632

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • Aurora A

    Aurora A, IC50:27 nM

  • Aurora B

    Aurora B, IC50:135 nM

  • Aurora C

    Aurora C, IC50:120 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
U266 1 μM 24 hours Increased NIK protein levels PMC6959191
JJN3 1 μM 24 hours Increased NIK protein levels PMC6959191
RPMI-8226 1 μM 24 hours Increased NIK protein levels PMC6959191
OPM-2 1 μM 24 hours Increased NIK protein levels PMC6959191
OVCAR10 cells 500 nM 24 hours Assessed the effect of PHA-680632 on cell cycle, showing accumulation of cells in the 4N (G2/M) compartment and appearance of a significant >4N cell population. PMC3204164
A549 (p53 wild-type) 200 nM 24 hours To evaluate the effect of PHA680632 on radiation response, results showed that in p53 wild-type A549 cells, PHA680632 had little effect on radiation response (DER=0.994 at 2 Gy). PMC2360282
HT29 (p53 mutant) 1 μM 24 hours To evaluate the effect of PHA680632 on radiation response, results showed that in p53 mutant HT29 cells, PHA680632 significantly increased the radiation effect (P<0.0001), showing a supra-additive effect (DER=1.205 at 2 Gy). PMC2360282
HCT116 (p53-deficient) 100 nM 24 hours To evaluate the effect of PHA680632 on radiation response, results showed that in p53-deficient HCT116 cells, PHA680632 significantly increased the radiation effect (P<0.0001), showing a supra-additive effect (DER=1.348 at 1 Gy and DER=1.285 at 2 Gy). PMC2360282
HCT116 (p53 wild-type) 100 nM 24 hours To evaluate the effect of PHA680632 on radiation response, results showed that in p53 wild-type HCT116 cells, PHA680632 increased the radiation effect (P<0.0001), but the effect decreased with increasing radiation dose, showing a sub-additive effect (DER=0.872 at 2 Gy). PMC2360282
Normal primary human ovarian surface epithelial (HOSE) cell lines 500 nM 72 hours Assessed synergy between PHA-680632 and dasatinib in inhibiting cell growth, showing no synergy in 0/3 HOSE cell lines. PMC3204164
Human epithelial ovarian cancer (EOC) cell lines 500 nM 72 hours Assessed synergy between PHA-680632 and dasatinib in inhibiting cell growth, showing strong synergy in 8/8 EOC cell lines. PMC3204164

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice P53-deficient HCT116 subcutaneous xenograft Intraperitoneal injection 40 mg/kg Twice daily for 4 days To evaluate the effect of PHA680632 combined with radiation, results showed that PHA680632 alone significantly inhibited tumor growth, and when combined with radiation, it showed an additive effect (P=0.0685). PMC2360282
NOD-SCID mice Multiple myeloma xenograft model Subcutaneous injection 50 mg/kg Two weeks Evaluate the anti-tumor effect of PHA-680632 PMC6959191

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.97mL

1.99mL

1.00mL

19.94mL

3.99mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories